GPT and metabolic dysfunction-associated steatohepatitis: The role of variant E167K in TM6SF2 was first described by Kozlitina et al. [36] in an exome-wide association study in a multiethnic, population-based cohort, highlighting the association of the TM6SF2 variant with higher serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels—as surrogates for NASH—and with reduced plasma levels of triglycerides and low density lipoprotein- (LDL-) cholesterol.